Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Stock Information for Medicus Pharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medicus Pharma Ltd.

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.